A randomized controlled clinical trial on efficacy and safety of anakinra in patients with severe COVID-19.
Amir Behnam KharazmiOmid MoradiMehrdad HaghighiMehran KouchekAlireza Manafi-RasiMasoomeh RaoufiSimin Dokht ShoaeiFahimeh HadavandMahmood NabaviMir Mohammad MiriSara SalarianSeyedpouzhia ShojaeiShayesteh KhaliliMohammad SistanizdSetayesh SadeghiAmirhossein KaragahSaemeh AsgariMorteza JaffaraghaeiShahram AraghiPublished in: Immunity, inflammation and disease (2021)
Anakinra as an immunomodulatory agent has been associated with the reduced need for mechanical ventilation in patients admitted to intensive care units because of severe COVID-19. The medication reduced the hospital length of stay. Furthermore, no increased risk of infection was observed. Further randomized placebo-controlled trials with a larger sample size are needed to confirm these findings.
Keyphrases
- mechanical ventilation
- placebo controlled
- intensive care unit
- coronavirus disease
- double blind
- sars cov
- acute respiratory distress syndrome
- phase iii
- phase ii
- healthcare
- early onset
- adverse drug
- respiratory failure
- open label
- study protocol
- respiratory syndrome coronavirus
- squamous cell carcinoma
- extracorporeal membrane oxygenation
- drug induced
- randomized controlled trial
- emergency department